Published in Bioconjug Chem on September 18, 2002
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A (2013) 1.20
'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res (2002) 1.08
Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A (2005) 1.06
In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol Pharm (2009) 1.02
TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS One (2012) 1.00
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res (2003) 0.98
A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A (2003) 0.98
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A (2007) 0.96
Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol Ther (2009) 0.93
Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation. Immunology (2008) 0.89
Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res (2013) 0.89
Improved systemic pharmacokinetics, biodistribution, and antitumor activity of CpG oligodeoxynucleotides complexed to endogenous antibodies in vivo. J Control Release (2007) 0.88
Broad-spectrum drugs against viral agents. Int J Mol Sci (2008) 0.81
Conjugation of lipid and CpG-containing oligonucleotide yields an efficient method for liposome incorporation. Bioconjug Chem (2011) 0.79
Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications. Nucleic Acids Res (2006) 0.78
Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses. ACS Med Chem Lett (2013) 0.75
Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Antimicrob Agents Chemother (2008) 0.75
Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A (2003) 4.37
MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem (2004) 1.93
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A (2003) 1.87
Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol (2004) 1.60
Human cytomegalovirus UL38 protein blocks apoptosis. J Virol (2007) 1.55
Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Clin Cancer Res (2002) 1.55
Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene (2005) 1.51
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene (2004) 1.47
Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun (2006) 1.45
Compared study of Asian reduction malarplasty: wedge-section osteotomy versus conventional procedures. J Craniofac Surg (2009) 1.41
Human cytomegalovirus protein pUL38 induces ATF4 expression, inhibits persistent JNK phosphorylation, and suppresses endoplasmic reticulum stress-induced cell death. J Virol (2009) 1.38
Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity. Am J Physiol Gastrointest Liver Physiol (2002) 1.34
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate (2003) 1.22
Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res (2006) 1.22
The full-length protein encoded by human cytomegalovirus gene UL117 is required for the proper maturation of viral replication compartments. J Virol (2008) 1.18
UL26-deficient human cytomegalovirus produces virions with hypophosphorylated pp28 tegument protein that is unstable within newly infected cells. J Virol (2006) 1.15
Protease-activated receptor-2 protects against pancreatitis by stimulating exocrine secretion. Gut (2006) 1.13
'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res (2002) 1.08
Point mutations in exon I of the herpes simplex virus putative terminase subunit, UL15, indicate that the most conserved residues are essential for cleavage and packaging. J Virol (2003) 1.07
The human cytomegalovirus gene UL79 is required for the accumulation of late viral transcripts. J Virol (2011) 1.06
Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A (2005) 1.06
Inhibition of cyclooxygenase-2 ameliorates the severity of pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol (2002) 1.06
Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther (2006) 1.05
Thermal stress-induced HSP70 mediates protection against intrapancreatic trypsinogen activation and acute pancreatitis in rats. Gastroenterology (2002) 1.05
Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc Natl Acad Sci U S A (2007) 1.05
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res (2006) 1.05
Human cytomegalovirus pUS24 is a virion protein that functions very early in the replication cycle. J Virol (2006) 1.02
Murine cytomegalovirus targets transcription factor ATF4 to exploit the unfolded-protein response. J Virol (2012) 1.02
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. Int J Radiat Oncol Biol Phys (2007) 1.01
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res (2011) 1.00
TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS One (2012) 1.00
Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640. Ann N Y Acad Sci (2005) 1.00
Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J Med Chem (2009) 1.00
A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A (2003) 0.98
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res (2003) 0.98
Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr Cancer Drug Targets (2005) 0.98
Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study. Cardiovasc Diabetol (2012) 0.98
Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J Med Chem (2009) 0.97
Human cytomegalovirus protein pUL117 targets the mini-chromosome maintenance complex and suppresses cellular DNA synthesis. PLoS Pathog (2010) 0.97
Inactivation of enveloped virus by laser-driven protein aggregation. J Biomed Opt (2012) 0.96
Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int J Radiat Oncol Biol Phys (2004) 0.96
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A (2007) 0.96
In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injury. Am J Physiol Lung Cell Mol Physiol (2002) 0.95
Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res (2009) 0.94
Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res (2004) 0.94
Erratum: Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. Nature (2015) 0.93
Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol Ther (2009) 0.93
Human cytomegalovirus gene UL21a encodes a short-lived cytoplasmic protein and facilitates virus replication in fibroblasts. J Virol (2010) 0.93
Murine cytomegalovirus protein pM79 is a key regulator for viral late transcription. J Virol (2013) 0.92
Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity. Bioconjug Chem (2010) 0.92
A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity (2013) 0.91
Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol Cancer Ther (2010) 0.91
Human cytomegalovirus early protein pUL21a promotes efficient viral DNA synthesis and the late accumulation of immediate-early transcripts. J Virol (2010) 0.91
Vapor-liquid-solid and vapor-solid growth of phase-change Sb2Te3 nanowires and Sb2Te3/GeTe nanowire heterostructures. J Am Chem Soc (2008) 0.91
A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol (2013) 0.91
Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther (2006) 0.91
Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate (2004) 0.91
Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. Prostate (2008) 0.91
Effects of different factors of ultrasound treatment on the extraction yield of the all-trans-β-carotene from citrus peels. Ultrason Sonochem (2010) 0.90
Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. J Med Chem (2002) 0.90
Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun (2002) 0.90
Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med (2002) 0.90
Proteasome-dependent disruption of the E3 ubiquitin ligase anaphase-promoting complex by HCMV protein pUL21a. PLoS Pathog (2012) 0.90
Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum Mol Genet (2013) 0.90
An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS One (2012) 0.89
Genetic analysis of an elite super-hybrid rice parent using high-density SNP markers. Rice (N Y) (2013) 0.89
Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. J Allergy Clin Immunol (2007) 0.89
Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res (2013) 0.89